Cequr Raises $115 Million Series C5 Financing To Support Commercialization And Scale-Up Of Automated Manufacturing For Cequr Simplicity Wearable Insulin-Delivery Device

CeQur®, a medical device company committed to simplifying the lives of people with diabetes by revolutionizing insulin-delivery solutions, today announced the close of an oversubscribed $115 million equity financing. The company will use the funds to advance commercial plans for CeQur SimplicityTM, including market development activities, a phased commercial launch strategy that includes a limited market release in 2021, and the scale-up of high-volume manufacturing. CeQur Simplicity is both FDA cleared and CE-marked.